UPEC-FimON
/ Hopec Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 20, 2026
Phase I Study of Inactivated UPEC-FimON for Non Muscle Invasive Bladder Cancer After BCG or Intravesical Chemotherapy Failure
(clinicaltrials.gov)
- P1 | N=30 | Recruiting | Sponsor: Hopec Pharma
New P1 trial • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer
1 to 1
Of
1
Go to page
1